Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial

HDV infection leads to the most aggressive form of human viral hepatitis for which there is no FDA-approved therapy. PEG IFN-lambda-1a (Lambda) has previously demonstrated a good tolerability profile in HBV and HCV patients compared to PEG IFN-alfa. The goal of Phase 2 LIMT-1 trial was to evaluate t...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Hepatology (Baltimore, Md.) Md.), 2023-06, Vol.77 (6), p.2093-2103
Hauptverfasser:	Etzion, Ohad, Hamid, Saeed, Lurie, Yoav, Gane, Edward J, Yardeni, David, Duehren, Sarah, Bader, Nimrah, Nevo-Shor, Anat, Channa, Saleh Muhammad, Cotler, Scott J, Mawani, Minaz, Parkash, Om, Dahari, Harel, Choong, Ingrid, Glenn, Jeffrey S
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - adverse effects Drug Therapy, Combination Hepatitis D, Chronic - drug therapy Humans Hyperbilirubinemia - chemically induced Interferon-alpha - adverse effects Interleukins - genetics Original : Viral Hepatitis Polyethylene Glycols - adverse effects Recombinant Proteins - adverse effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!